Literature DB >> 58033

Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG).

P Minden, T R Sharpton, J K McClatchy.   

Abstract

This study was undertaken to investigate the antigenic relationships between human malignant melanoma cells and Mycobacterium bovis (BCG). Rabbits were immunized with sonicates of BCG or with malignant melanoma cells from different patients and the resulting antisera were tested for their capacity to bind radiolabeled soluble extracts prepared from BCG and melanoma cells. The binding of antibodies to radiolabeled antigens was studied by precipitation of radiolabeled antigen-antibody complexes by anti-rabbit immunoglobulin. Antibodies in sera from rabbits immunized with either BCG (anti-BCG) or melanoma cells (anti-melanoma) bound both the labeled BCG and melanoma antigens. Control antisera, from rabbits immunized with human acute or chronic lymphatic leukemia cells or with normal human spleen cells, did not bind significant amounts of radiolabeled BCG. Antibodies in sera from rabbits immunized with normal spleen cells bound small but significant amounts of radiolabeled melanoma antigens. Binding by anti-BCG and anti-melanoma to the radiolabeled antigens was studied before and after absorption of antisera with cells from human melanoma, leukemia, guinea pig hepatoma, and normal human spleen cells. Inhibition studies using unlabeled BCG extracts also were carried out. The absorption and inhibition studies confirmed that the binding reactions were specific and that antigens from five melanoma patients shared antigenic determinants with BCG.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 58033

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Immunological method to differentiate between antigens of tubercle bacilli, other mycobacterial species, and non-acid-fast bacteria.

Authors:  H R Ferguson; J K McClatchy; T R Sharpton; P Minden
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

2.  Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guèrin)BCG monoclonal antibody.

Authors:  J Sasaki; T Tamagake; S Narita; C R Ahsan
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

4.  Delayed-type hypersensitivity to rabies virus in mice: assay of active or passive sensitization by the footpad test.

Authors:  P H Lagrange; H Tsiang; B Hurtrel; P Ravisse
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

Review 5.  Mycobacterial antigens: a review of their isolation, chemistry, and immunological properties.

Authors:  T M Daniel; B W Janicki
Journal:  Microbiol Rev       Date:  1978-03

Review 6.  Mycobacterium.

Authors:  L Barksdale; K S Kim
Journal:  Bacteriol Rev       Date:  1977-03

7.  A solid-phase radioimmunoassay to detect antibodies produced by hybridomas to antigens derived from human melanoma cells.

Authors:  P J Kelleher; H L Mathews; L K Woods; R S Farr; P Minden
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Antigen capture assay for detection of a 43-kilodalton Mycobacterium tuberculosis antigen.

Authors:  A A Wadee; L Boting; S G Reddy
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

9.  The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.

Authors:  N Cascinelli; P Rümke; R MacKie; A Morabito; R Bufalino
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  The use of cellular immunoadsorbents to prepare polyclonal antibodies that distinguish between antigens derived from human melanoma cells and autologous lymphocytes.

Authors:  P J Kelleher; H L Mathews; G E Moore; P Minden
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.